These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23793142)

  • 1. Usefulness of the PERFORM questionnaire to measure fatigue in cancer patients with anemia: a prospective, observational study.
    Gascón P; Rodríguez CA; Valentín V; Mata JG; Carulla J; Cassinello J; Colomer R; Baró E
    Support Care Cancer; 2013 Nov; 21(11):3039-49. PubMed ID: 23793142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychometric properties of the Perform Questionnaire: a brief scale for assessing patient perceptions of fatigue in cancer.
    Baró E; Carulla J; Cassinello J; Colomer R; Mata JG; Gascón P; Gasquet JA; Rodríguez CA; Valentín V
    Support Care Cancer; 2011 May; 19(5):657-66. PubMed ID: 20432046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.
    Hudis CA; Vogel CL; Gralow JR; Williams D;
    Clin Breast Cancer; 2005 Jun; 6(2):132-42. PubMed ID: 16001991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.
    Cartenì G; Giannetta L; Ucci G; De Signoribus G; Vecchione A; Pinotti G; Puglisi F; Contillo A; Pezzella G; Orecchia S; Beccaglia P;
    Support Care Cancer; 2007 Sep; 15(9):1057-66. PubMed ID: 17431689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
    Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
    Oncologist; 2006 Feb; 11(2):206-16. PubMed ID: 16476841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.
    Mel JR; Salar A; Rodríguez CA; Alegre A; González A; Cassinello J; Montesinos J; Gasquet JA; Sánchez J; Saigí E;
    Curr Med Res Opin; 2008 Oct; 24(10):2931-42. PubMed ID: 18775103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.
    Gabrilove JL; Cleeland CS; Livingston RB; Sarokhan B; Winer E; Einhorn LH
    J Clin Oncol; 2001 Jun; 19(11):2875-82. PubMed ID: 11387360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective cohort study on the impact of darbepoetin alfa on quality of life in daily practice following anemia treatment guideline revisions.
    Steinmetz T; Kindler M; Lange O; Vehling-Kaiser U; Kuhn A; Hellebrand E
    Curr Med Res Opin; 2014 Sep; 30(9):1813-20. PubMed ID: 24849527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.
    Canon JL; Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Legg J; Pujol B; Bridges K
    Med Oncol; 2012 Sep; 29(3):2291-9. PubMed ID: 22081263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An induction dose of epoetin alpha of 40 000 IU daily for three consecutive days increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Mustacchi G; Ceccherini R; Dellach C; Foladore S; Milani S; Leita M; Sisto M
    Ann Oncol; 2006 Nov; 17(11):1705-8. PubMed ID: 16980603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Darbepoetin alpha as treatment for anemia in patients receiving chemotherapy: a single-center experience.
    Bartsch R; Wenzel C; Sevelda U; Hussian D; Pluschnig U; Locker GJ; Mader R; Zielinski CC; Steger GG
    Anticancer Drugs; 2005 Jul; 16(6):617-20. PubMed ID: 15930888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in haemoglobin level.
    Esquerdo G; Llorca C; Cervera JM; Orts D; Juárez A; Carrato A
    Clin Transl Oncol; 2011 May; 13(5):341-7. PubMed ID: 21596663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
    Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
    Oncologist; 2006 Feb; 11(2):197-205. PubMed ID: 16476840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-weekly dose of epoetinum alfa in cancer patients with anemia receiving radiotherapy.
    Ots PM; Pérez AR; Carrizosa CL; Ocaña CV; de Dios Sáez Garrido J; Delgado Pérez JM
    Clin Transl Oncol; 2005 Dec; 7(11):486-92. PubMed ID: 16373059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
    Martelli O; Garassino M; Sacchetta S; Caristo R; Zivi A; Cerbone L; Mancuso A
    Anticancer Res; 2008; 28(3B):1767-71. PubMed ID: 18630457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standard of care for cancer-related anemia: improving hemoglobin levels and quality of life.
    Cortesi E; Gascón P; Henry D; Littlewood T; Milroy R; Pronzato P; Reinhardt U; Shasha D; Thatcher N; Wilkinson P
    Oncology; 2005; 68 Suppl 1():22-32. PubMed ID: 15855813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a fatigue and functional impact scale in anemic cancer patients receiving chemotherapy.
    Cella D; Viswanathan HN; Hays RD; Mendoza TR; Stein KD; Pasta DJ; Foreman AJ; Vadhan-Raj S; Kallich JD
    Cancer; 2008 Sep; 113(6):1480-8. PubMed ID: 18642348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.
    Santini D; Vincenzi B; La Cesa A; Virzi V; Navajas F; Malafarina V; Dicuonzo G; Cassandro R; Esposito V; Montesarchio V; Groeger AM; Tonini G
    Anticancer Res; 2005; 25(1B):669-74. PubMed ID: 15816644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
    Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.